ACE-031 1mg 1kit

ACE-031 Product Overview

ACE-031 is an investigational recombinant fusion protein designed to interfere with biological signals that regulate skeletal muscle growth. It combines the extracellular domain of activin receptor type IIB (ActRIIB) with the Fc region of human immunoglobulin G1 (IgG1).

The compound was developed to investigate whether binding myostatin and related signalling molecules could influence muscle mass and function. Its research programme included investigations into muscle-wasting conditions, particularly Duchenne muscular dystrophy.

Unlike conventional synthetic peptides, ACE-031 is a larger, engineered biological molecule. Its interaction with multiple members of the transforming growth factor beta (TGF-β) superfamily makes it relevant to research into muscle biology and receptor signalling. However, clinical development was discontinued after safety concerns emerged, and ACE-031 is not an approved medicine.

Key Features and Research Background

• Recombinant fusion protein: ACE-031 combines a receptor-derived protein domain with an antibody-derived Fc region.

• ActRIIB-based design: Its molecular structure allows it to bind selected extracellular signalling molecules.

• Myostatin research: It was investigated for its interaction with myostatin, a protein involved in regulating skeletal muscle growth.

• Broader ligand interactions: ACE-031 can interact with other signalling molecules, including activin-related ligands.

• Clinical research history: Human studies examined its pharmacological activity, muscle-related measurements, and safety.

• Important safety context: Clinical development was discontinued following safety concerns involving vascular-related effects.

These characteristics describe ACE-031’s molecular design and research history. They do not establish the identity, purity, or safety of any particular commercial product.

Specifications

The following details describe ACE-031 as a molecule. Specifications for an individual commercial product must be verified separately.

• Product name: ACE-031

• Alternative name: Ramatercept

• Molecule type: Recombinant fusion protein

• Molecular design: Extracellular domain of human activin receptor type IIB fused to human IgG1 Fc

• Primary research area: Myostatin and activin-related signalling

• Development status: Clinical development discontinued

• Regulatory status: Not an approved medicine

• Product quantity: Refer to the specific listing.

• Purity and formulation: Confirm through appropriate product-specific analytical documentation.

ACE-031 is a complex biological molecule. A product label alone does not establish that a material contains the intended fusion protein. Verification requires appropriate analytical evidence supporting its molecular identity and composition.

How It Works and What’s Included

ACE-031 was designed to function as a soluble decoy receptor. It binds selected extracellular signalling proteins, potentially preventing them from interacting with their normal cell-surface receptors.

One important target is myostatin, a signalling protein involved in limiting skeletal muscle growth. ACE-031 also interacts with other ligands in related pathways, making its biological activity broader than selective myostatin inhibition alone.

This broader activity is important when interpreting its research history. Clinical investigations identified safety concerns, including nosebleeds and telangiectasias, which are small, visibly dilated blood vessels. These findings contributed to the discontinuation of its development.

When evaluating an ACE-031 product, review its stated identity, composition, and supporting analytical documentation. The exact contents of a commercial listing cannot be assumed without product-specific information. Do not assume that solvents, laboratory accessories, certificates, or other materials are included unless explicitly documented.

ACE-031 should not be used for self-administration or treated as an established muscle-building treatment. Its experimental mechanism does not establish safety or effectiveness for human use.

Why Choose Titan Research Peptides?

Titan Research Peptides provides an online catalogue for customers exploring research-focused compounds. Product listings allow buyers to review available information and compare materials according to their research interests.

For ACE-031, product verification is particularly important because the compound is a recombinant fusion protein rather than a conventional short-chain peptide. Appropriate documentation should support the identity and composition of the material being offered.

Review the current listing for stated specifications and any available analytical information. If an important detail is missing, request clarification rather than assuming that the commercial material matches the protein studied in published research.

Related Research Products at Titan Research Peptides

Researchers exploring muscle-related signalling and endocrine pathways may also wish to examine other compounds in the Titan Research Peptides catalogue. These products have different molecular structures and research backgrounds, so they should be evaluated independently.

• IGF-1 LR3: A modified form of insulin-like growth factor 1 investigated in research involving cellular growth and signalling.

• CJC-1295: A synthetic growth hormone-releasing hormone analogue studied in relation to endocrine signalling.

• Ipamorelin: A synthetic peptide investigated for its activity at the ghrelin receptor and its relationship with growth hormone secretion.

• Tesamorelin: A synthetic growth hormone-releasing hormone analogue investigated in endocrine and metabolic research.

• BPC-157: A synthetic peptide studied in preclinical experimental research involving various biological processes.

• TB-500: A product name associated with thymosin beta-4-related research materials. The exact identity and composition should be verified for each listing.

These compounds are not equivalent to ACE-031. ACE-031 is a recombinant fusion protein that interacts with myostatin and related ligands, while the listed compounds have different structures and biological targets.

Visit the Titan Research Peptides shop to check current product availability and identify relevant listings for internal linking.

Frequently Asked Questions

What is ACE-031?

ACE-031 is an investigational recombinant fusion protein designed to bind myostatin and other signalling molecules involved in muscle growth regulation. It was studied for potential applications in muscle-wasting conditions, but clinical development was discontinued following safety concerns.

Is it a peptide?

ACE-031 is more accurately described as a recombinant fusion protein than a conventional synthetic peptide. It combines an extracellular receptor domain with an antibody-derived Fc region. This distinction matters when evaluating its molecular identity and the analytical methods required to verify a commercial product.

Why was ACE-031 discontinued?

Clinical development was discontinued after safety concerns emerged, including nosebleeds and telangiectasias. These findings raised concerns about the compound’s broader biological effects beyond the intended muscle-related signalling pathways.

Is it approved for human use?

No. ACE-031 is not an approved medicine. Its clinical development was discontinued, and its experimental mechanism does not establish that it is safe or effective for muscle growth or another medical purpose.

What should I check when evaluating an ACE-031 product?

Review the stated molecular identity, composition, quantity, and available analytical documentation. Because ACE-031 is a recombinant fusion protein, verification should establish whether the material matches the intended molecule rather than relying solely on its product label or an unsupported purity claim.

Titan Research Peptides

ACE-031 is an important example of research into muscle-growth regulation and the complexity of targeting biological signalling pathways. Its interaction with myostatin and related ligands has contributed to scientific investigations of the activin receptor pathway, while its discontinued clinical programme highlights the importance of evaluating safety alongside potential biological activity.

Explore the ACE-031 listing at Titan Research Peptides to review the available product information and supporting documentation. Consider its molecular identity, research history, and safety limitations when evaluating the compound, and do not assume that a commercial product represents the authentic fusion protein without appropriate verification.